Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires. On February 5, Arrowhead Pharmaceuticals achieved a strategic turning point in FQ1 2026, transitioning into a commercial-stage organization following the US FDA approval of its first medicine, REDEMPLO (plozasiran). This siRNA therapeutic, designed to treat familial chylomicronemia syndrome/FCS, also received regulatory clearances in China and Canada.

The US launch has shown early momentum with over 100 initial prescriptions and the establishment of a dedicated patient support program, marking a major milestone in the company’s history. The company’s research and development pipeline reached several technical landmarks, highlighted by the initiation of a Phase 1/2a trial for ARO-DIMER-PA, the industry’s first dual-function clinical candidate to target two genes in one molecule. Additionally, Arrowhead reported encouraging interim data from its obesity programs, where ARO-INHBE showed a significant weight loss advantage when combined with tirzepatide. The firm also advanced its CNS efforts by dosing the first subjects in a trial for ARO-MAPT, which uses a new delivery system capable of crossing the blood-brain barrier.

Jirsak/Shutterstock.com

Financially, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) swung to a net income of $30.8 million for the quarter, a sharp contrast to the $173.1 million loss in the prior year period. This profitability was driven by a surge in revenue to $264 million, fueled by a $200 million upfront payment from a new global collaboration with Novartis and a $200 million milestone from Sarepta Therapeutics.

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) develops medicines for the treatment of intractable diseases in the US. Its pipeline primarily includes Plozasiran, Zodasiran, ARO-DIMER-PA, and ARO-PNPLA3.

While we acknowledge the potential of ARWR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.